ReviewJACC. Basic to translational science2020
Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.
Review in JACC. Basic to translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Insights from 3D echocardiography: unveiling the prognostic value of RV function in pulmonary hypertension: a systematic review and meta-analysis.The international journal of cardiovascular imaging · 2025Pooled it
- Prognostic value of right ventricular free-wall longitudinal strain in patients with pulmonary hypertension: systematic review and meta-analyses.Open heart · 2024Pooled it
- Multimodality Molecular Profiling Nominates Targetable Mechanisms in Progressive RV Dysfunction.Circulation research · 2026Article
- The β1 adrenoceptor (AR) blocker metoprolol normalises βAR cascade and caveolar protein expression and restores β1AR responsiveness in failing right ventricular myocytes.Journal of molecular and cellular cardiology plus · 2026Article
- Large animal models of right heart failure due to pulmonary hypertension: a bridge to translational success.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Cardiometabolic reprogramming in pulmonary arterial hypertension: Implications for right ventricular dysfunction and therapeutic strategies.Chinese herbal medicines · 2026Review
- Pulmonary arterial hypertension induces a metabolic and inflammatory hepatopathy.The Journal of clinical investigation · 2026Article
- Activation of α7nAChR prevents maladaptive right ventricular remodeling via inhibiting the recruitment of CCR2Respiratory research · 2026Article
- Pulmonary Arterial Hypertension Induces a Metabolic and Inflammatory Hepatopathy.bioRxiv : the preprint server for biology · 2026Article
- Multimodality Molecular Profiling Nominates Targetable Mechanisms in Progressive RV Dysfunction.bioRxiv : the preprint server for biology · 2026Article
- The right kind of rarefaction: Coronary microvascular remodeling in right ventricle failure.JHLT open · 2026Article
- Association of Immunoglobulin E With Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.Pulmonary circulation · 2026Article
- Focused Echocardiography to Guide Management in Acute Decompensated Heart Failure: From Rapid Phenotyping to Therapeutic Precision : Short title: Focused Echocardiography in the Management of Acute Decompensated Heart Failure.Galen medical journal · 2026Article
- Ferroptosis in veterinary medicine: mechanisms, therapies, and unmet challenges.The veterinary quarterly · 2025Review
- Roles of Lipid Metabolism in Pulmonary Hypertension: Friend or Foe?Biomolecules · 2025Review
- Meldonium Improves Functional Capacity in Patients with Right Ventricular Failure.Journal of clinical medicine · 2025Article
- Adaptation to Elevated Mitochondrial Calcium Is Distinct in the Left and Right Ventricles.Circulation research · 2025Article
- GP130 Antagonism Enhances Porcine RV Function.Circulation research · 2025Article
- Sotatercept: A novel therapeutic approach for pulmonary arterial hypertension through transforming growth factor-β signaling modulation.World journal of methodology · 2025Review
- Current landscape for connective tissue disease associated-pulmonary arterial hypertension: a focus on right ventricular adaptation and failure.Future cardiology · 2025Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. Although there are shared molecular mechanisms in both RV and left ventricle (LV) dysfunction, there are important differences between the 2 ventricles that may allow for the development of RV-enhancing or RV-directed therapies. In this review, we discuss the current understandings of the dysregulated pathways that promote RV dysfunction, highlight RV-enriched or RV-specific pathways that may be of particular therapeutic value, and summarize recent and ongoing clinical trials that are investigating RV function in PAH. It is hoped that development of RV-targeted therapies will improve quality of life and enhance survival for this deadly disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.